Efficacy of Cardiac Myosin Inhibitors Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: a Systematic Review and Meta-analysis of Randomised Controlled Trials

Overview

Journal Open Heart

Publisher BMJ Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2025 Feb 23

PMID 39988344

Authors

Ayesha Aman

Arfa Akram

Bisma Akram

Momina Maham

Masooma Zainab Bokhari

Aleena Akram

Sania Akram

Furqan Yaqub

Affiliations

Soon will be listed here.

Abstract

Background: Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes. This meta-analysis sought to determine the efficacy of mavacamten and aficamten in hypertrophic cardiomyopathy.

Methods: The online databases were searched from inception to July 2024, including the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, ClinicalTrials.gov. The meta-analytical data were pooled using risk ratios (RRs) with 95% CI, standard mean difference (SMD) and SE.

Results: A total of 6 randomised controlled trials with 826 hypertrophic cardiomyopathy patients (mean age±SD up to 59.8±14.2 years in intervention vs 60.9±10.5 years in placebo) were included in our study. Of these, 443 received a cardiac myosin inhibitor and 383 received a placebo. The resting left ventricular outflow tract (LVOT) gradient between the two groups was considerably improved by cardiac myosin inhibitors (MD -57.27; 95% CI -63.05 to -51.49). Significant differences were also observed in the post-Valsalva LVOT gradient between the two groups (MD -55.86; 95% CI -65.55 to -46.18). Significantly decreased left ventricle ejection fraction (LVEF) was also seen (MD -4.74; 95% CI -7.22 to -2.26). The New York Health Association (NYHA) class improvement between the two groups also changed significantly (RR 2.21; 95% CI 1.75 to 2.80). Cardiac myosin inhibitors also caused significant improvement in the Kansas City Cardiomyopathy Questionnaire in a Clinical Summary Score between the two groups (MD 7.71; 95% CI 5.37 to 10.05) and significant reduction in the N-terminal pro-B-type natriuretic peptide (SMD -13.27; 95% CI -17.51 to -9.03) and the cardiac troponin I (SMD -11.90; 95% CI -15.07 to -8.72).

Conclusion: According to our meta-analysis, cardiac myosin inhibitors significantly improve the resting and post-Valsalva LVOT gradient, reduce the LVEF and improve the NYHA class and cardiac biomarkers when compared with the placebo.

Prospero Registration Number: CRD52024586161.

References

Stern J, Markova S, Ueda Y, Kim J, Pascoe P, Evanchik M . A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS One. 2016; 11(12):e0168407. PMC: 5156432. DOI: 10.1371/journal.pone.0168407. View

Ding W, Meah M, Stables R, Cooper R . Interventions in Hypertrophic Obstructive Cardiomyopathy. Can J Cardiol. 2023; 40(5):833-842. DOI: 10.1016/j.cjca.2023.12.001. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Maron B, Maron M . Hypertrophic cardiomyopathy. Lancet. 2012; 381(9862):242-55. DOI: 10.1016/S0140-6736(12)60397-3. View

Papadakis M, Basu J, Sharma S . Mavacamten: treatment aspirations in hypertrophic cardiomyopathy. Lancet. 2020; 396(10253):736-737. DOI: 10.1016/S0140-6736(20)31793-1. View

Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V . Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis. Circulation. 2020; 143(6):606-608. DOI: 10.1161/CIRCULATIONAHA.120.052359. View

Capota R, Militaru S, Ionescu A, Rosca M, Baicus C, Popescu B . Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health Qual Life Outcomes. 2020; 18(1):351. PMC: 7602300. DOI: 10.1186/s12955-020-01604-9. View

Maron M, Ommen S . Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective. Circulation. 2021; 143(12):1181-1183. DOI: 10.1161/CIRCULATIONAHA.120.051330. View

Desai M, Owens A, Geske J, Wolski K, Naidu S, Smedira N . Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol. 2022; 80(2):95-108. DOI: 10.1016/j.jacc.2022.04.048. View

10.

Maron B . Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287(10):1308-20. DOI: 10.1001/jama.287.10.1308. View

11.

Iavarone M, Monda E, Vritz O, Calila Albert D, Rubino M, Verrillo F . Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy. Arch Cardiovasc Dis. 2022; 115(10):529-537. DOI: 10.1016/j.acvd.2022.06.003. View

12.

Critoph C, Patel V, Mist B, Elliott P . Cardiac output response and peripheral oxygen extraction during exercise among symptomatic hypertrophic cardiomyopathy patients with and without left ventricular outflow tract obstruction. Heart. 2014; 100(8):639-46. DOI: 10.1136/heartjnl-2013-304914. View

13.

Quintana E, Bajona P, Myers P . Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021; 397(10272):369. DOI: 10.1016/S0140-6736(20)32384-9. View

14.

Zhu L, Li C, Liu Q, Xu W, Zhou X . Molecular biomarkers in cardiac hypertrophy. J Cell Mol Med. 2019; 23(3):1671-1677. PMC: 6378174. DOI: 10.1111/jcmm.14129. View

15.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

16.

Rangwala H, Fatima H, Ali M, Taha Ahmed S, Rangwala B, Abbas S . Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis. Egypt Heart J. 2023; 75(1):99. PMC: 10693538. DOI: 10.1186/s43044-023-00427-5. View

17.

Bertero E, Chiti C, Schiavo M, Tini G, Costa P, Todiere G . Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population. Eur J Heart Fail. 2023; 26(1):59-64. DOI: 10.1002/ejhf.3120. View

18.

Woodland M, Al-Horani R . New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Cardiovasc Hematol Agents Med Chem. 2022; 21(2):78-83. PMC: 10249146. DOI: 10.2174/1871525721666221019095218. View

19.

Yassen M, Changal K, Busken J, Royfman R, Schodowski E, Venkataramany B . The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review. Am J Cardiol. 2023; 210:219-224. DOI: 10.1016/j.amjcard.2023.10.059. View

20.

Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y . Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review. Heart Lung Circ. 2023; 32(9):1049-1056. DOI: 10.1016/j.hlc.2023.05.019. View